I'm A Patient
I'm A Provider
You know the frustration of delivering a dry AMD diagnosis when your only option is to recommend supplements and schedule regular monitoring. Your patients leave feeling worried about their future vision, and you’re left wishing you could offer more than just a “wait and see” approach.
MacuMira changes this dynamic by giving you the first authorised treatment that can actively improve visual function in dry AMD patients, allowing you to intervene early rather than waiting for vision loss to progress. This breakthrough in dry AMD treatment offers a new path forward for both you and your patients.
Why Early Action Matters in Dry AMD Management
Traditional dry AMD management puts you and your patients in a waiting game. You monitor progression through regular visits while recommending lifestyle changes and supplements, but you can’t actively treat the condition affecting their retinal pigment epithelium cells.
Your patients experience gradual changes that affect their daily routines. Reading becomes harder, driving feels less safe, and recognising faces grows more difficult. These functional changes happen slowly, making it easy to dismiss early symptoms until significant vision loss occurs.
The gap between diagnosis and meaningful intervention often spans years. During this time, cellular damage continues while you and your patients feel powerless to stop or reverse the progression.
How MacuMira Changes the Treatment Timeline
MacuMira represents the first authorised device designed to improve visual function for those affected by dry AMD. This breakthrough moves you from prevention-only strategies to active interventions that can help preserve and, potentially, improve your patients’ vision.
The treatment uses precisely delivered microcurrent to stimulate retinal pigment epithelium cells, enhancing mitochondrial activity to support cellular energy production. Your patients receive this noninvasive therapy without needles, injections, or downtime.
- Each session takes just 32 minutes with comfortable electrode placement around the eyes
- Patients can resume normal activities immediately after treatment
- Clinical trials showed 100% of participants experienced some level of visual function improvement
Earlier Intervention Before Advanced Stages
MacuMira works most effectively during early to intermediate dry AMD stages, when retinal pigment epithelium cells still have the capacity to respond to stimulation. You can start treatment as soon as you confirm the diagnosis, rather than waiting for progression.
By supporting cellular function before significant damage occurs, you help preserve the foundation of your patients’ central vision. This proactive approach can help slow functional decline and potentially improve existing visual capabilities.
What Makes MacuMira Different from Traditional Prevention Methods
While AREDS2 supplements and lifestyle modifications remain important, they work passively to slow progression. MacuMira actively stimulates the affected cells, providing direct therapeutic intervention at the cellular level.
The microcurrent technology enhances mitochondrial activity in retinal pigment epithelium cells, supporting their natural energy production processes. This active stimulation helps cells function more effectively, potentially reversing some of the decline associated with dry AMD.
- Targeted cellular stimulation addresses the root of visual function decline
- Treatment enhances the cells’ ability to maintain photoreceptor health
- Results can complement existing prevention strategies for comprehensive care
Adding to Your Current AMD Management
MacuMira doesn’t replace your current AMD management protocol—it enhances it. Your patients can continue their AREDS2 supplements and healthy lifestyle habits while receiving active treatment for their condition.
This comprehensive approach gives you multiple tools to address dry AMD from different angles, creating a more robust treatment plan that addresses both prevention and active intervention.
Clinical Evidence for Early Intervention Success
Clinical trials demonstrate MacuMira’s effectiveness in improving visual function across different stages of dry AMD. The results show meaningful improvements that your patients can notice in their daily activities.
- 48% of patients improved by 10 or more letters on ETDRS visual acuity charts
- Average improvement of 8.2 letters represented a 25% increase in visual acuity
- No adverse effects occurred during the clinical trial period
- Improvements were maintained throughout the entire study duration
What This Means for Your Practice
These results let you offer genuine hope instead of just monitoring progression. Your patients can see measurable improvements in their vision, which builds confidence in your care and strengthens the therapeutic relationship.
Early treatment success also helps you position your practice as a leader in innovative eye care, attracting patients who want proactive treatment options for their dry AMD. Review the complete clinical research data to understand the full scope of treatment outcomes.
Getting Started with MacuMira in Your Practice
Implementation begins with identifying patients who can benefit from early intervention. Candidates include those with early to intermediate dry AMD who want to take active steps to preserve their vision.
The treatment protocol involves 4 sessions over 10 days, followed by quarterly maintenance treatments. This schedule fits easily into most practice workflows while providing patients with convenient access to ongoing care.
Support and Training for Your Team
MacuMira provides comprehensive training for your entire team when you add the device to your practice. This support helps you confidently discuss treatment options with newly diagnosed patients and manage the therapy protocol effectively.You’ll also receive ongoing support throughout the lifetime of your device, providing consistent, quality care as you build your dry AMD treatment programme. Connect with our eye care professionals’ resources to learn more about adding this treatment to your practice and offering your patients proactive intervention.
